2_use_case_name: Prostate Cancer, Genetic Risk, and Equitable Screening Study (ProGRESS) - Prostate Cancer Risk Prediction Model
3_agency: Department of Veterans Affairs
3_abr: VA
4_bureau: VHA: Veterans Health Administration
8_topic_area: Other
8_question_type: Research
10_commercial_ai: None of the above.
11_purpose_benefits: This risk model is being used within the framework of a nationwide, VA funded randomized controlled trial to deliver a precision prostate cancer screening intervention to research participants. The model uses machine learning components (e.g., training and validation sets from MVP and other external sources, LASSO-regularized Cox model) and genetic, ancestry, and self-report family history of prostate cancer data to develop and validate a risk prediction model to help stratify new participants into three distinct prostate cancer risk categories (low risk, average risk, high risk). The risk classification is then included as part of a comprehensive report, including a full risk model report from a VA-approved genetic testing laboratory, a monogenic genetic variant report from a VA-approved genetic testing laboratory, and a summary sheet which provide general information and risk-specific recommendations surrounding prostate cancer screening. The report is shared with the participant and their VA healthcare providers as additional information to be used within the  framework of shared decision-making regarding future prostate cancer screening. 
12_outputs: The risk model uses new participant data to output a risk classification for prostate cancer based on genetic, ancestry, and self-report family history of prostate cancer data (low risk, average risk, high risk). The classification is is then included as part of a comprehensive report that is delivered to the participant and their VA healthcare providers to be used within the framework of shared decision-making regarding future prostate cancer screening.
16_dev_stage: Acquisition and/or Development
17_impact_type: Both
18_date_initiated: 8/1/2023
19_date_acq_dev_began: 3/1/2024
22_dev_method: Developed with both contracting and in-house resources.
23_contract_piids: 36C24124D0061, 36C24124C0018
24_hisp_support: No
27_public_info: No
29_contains_pii: Yes
30_saop_review: Yes
31_data_catalog: Other
31_question_type: Model was developed and validated by VA researchers using Million Veteran Program (MVP) data available only to approved researchers. Model translation to a genetic test and intervention materials are being developed by a VA-approved genetic testing laboratory.
33_agency_data: Million Veteran Program (MVP) data
34_data_docs: Documentation is complete: Documentation exists regarding the maintenance, composition, quality, and intended use of the training and evaluation data, as well as any statistical bias across model features and protected groups. 
35_demo_features: Race/Ethnicity
35_question_type: Model is specific to prostate cancer, so is only applicable to persons of male sex (not a specific variable in the model). Race/ethnicity data is genetically inferred ancestry.
37_custom_code: Yes
38_code_access: Yes – agency has access to source code, but it is not public.
39_code_link: Code is not publicly available, but is stored within VA systems (Genisis).
40_has_ato: No
42_dev_tools_wait: Less than 6 months
43_infra_provisioned: No
45_compute_request: Yes
47_timely_resources: Yes
49_existing_reuse: Use of existing data platforms: This use case is being developed on existing enterprise data and analytics platforms within the agency rather than procuring additional platforms or SaaS to operate.
50_internal_review: Documentation has been developed: Complete documentation detailing model performance across a range of benchmarks, architecture, relevant features and information regarding the appropriate use of the model for predictive tasks has been created.